levofloxacin has been researched along with virginiamycin in 9 studies
| Studies (levofloxacin) | Trials (levofloxacin) | Recent Studies (post-2010) (levofloxacin) | Studies (virginiamycin) | Trials (virginiamycin) | Recent Studies (post-2010) (virginiamycin) |
|---|---|---|---|---|---|
| 4,346 | 581 | 2,209 | 1,247 | 59 | 101 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (33.33) | 18.2507 |
| 2000's | 6 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tuohy, M; Washington, JA | 1 |
| Giamarellos-Bourboulis, EJ; Giamarellou, H; Grecka, P; Sambatakou, H | 1 |
| Heisig, P; Jones, ME; Klootwijk, M; Schmitz, FJ; Verhoef, J; Visser, MR | 1 |
| Cirioni, O; D'Amato, G; Del Prete, M; Ghiselli, R; Giacometti, A; Mocchegiani, F; Orlando, F; Saba, V; Scalise, G | 1 |
| Bercion, R; Carricajo, A; Celard, M; Chomarat, M; Croizé, J; Delubac, F; Fèvre, D; Frédénucci, I; Fuhrmann, C; Helfre, M; Lelièvre, H; Letouzey, MN; Mandjee, A; Marthelet, P; Meley, R; Perrier-Gros-Claude, JD; Ros, A; Roure, C; Smati, S; Thierry, J; Tous, J | 1 |
| Kilic, B; Kruse, M; Stahlmann, R | 1 |
| Kamel, AG; Lim, VK; Norazah, A; Rohani, MY | 1 |
| Gómez Gómez, J; López Fornás, F; Lorente Salinas, I; Martínez García, F; Pérez Salmerón, J; Roldán Conesa, D; Ruiz Gómez, J; Segovia Hernández, M; Valdés Chávarri, M | 1 |
| Flick, B; Kilic, B; Kruse, M; Stahlmann, R | 1 |
9 other study(ies) available for levofloxacin and virginiamycin
| Article | Year |
|---|---|
Antimicrobial susceptibility of viridans group streptococci.
Topics: Amoxicillin; Anti-Bacterial Agents; Cefazolin; Ceftriaxone; Clindamycin; Drug Resistance, Microbial; Gentamicins; Humans; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Ofloxacin; Penicillins; Rifampin; Streptococcal Infections; Streptococcus; Thienamycins; Vancomycin; Virginiamycin | 1997 |
In vitro activity of quinupristin/dalfopristin and newer quinolones combined with gentamicin against resistant isolates of Enterococcus faecalis and Enterococcus faecium.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; Enterococcus faecalis; Enterococcus faecium; Fluoroquinolones; Gentamicins; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Quinolones; Virginiamycin | 1998 |
Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-re
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Gentamicins; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines; Quinolones; Staphylococcus aureus; Vancomycin; Virginiamycin | 1999 |
Quinupristin/dalfopristin bonding in combination with intraperitoneal antibiotics prevent infection of knitted polyester graft material in a subcutaneous rat pouch model infected with resistant Staphylococcus epidermidis.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotic Prophylaxis; Disease Models, Animal; Doxycycline; Drug Therapy, Combination; Injections, Intraperitoneal; Levofloxacin; Male; Ofloxacin; Polyesters; Prosthesis-Related Infections; Rats; Staphylococcal Infections; Staphylococcus epidermidis; Virginiamycin | 2002 |
Comparative in vitro activity of penicillin G, levofloxacin, moxifloxacin, telithromycin, pristinamycin, quinupristin-dalfopristin and linezolid against ofloxacin-intermediate and -resistant Streptococcus pneumoniae.
Topics: Acetamides; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Ketolides; Lactams; Levofloxacin; Linezolid; Macrolides; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Oxazolidinones; Penicillin G; Pristinamycin; Quinolines; Streptococcus pneumoniae; Virginiamycin | 2002 |
The in vitro effects of quinupristin/dalfopristin, erythromycin and levofloxacin at low concentrations on the expression of different cell adhesion molecules on the surface of endothelial cells (Eahy926).
Topics: Anti-Bacterial Agents; Cell Adhesion Molecules; Cell Line; Dose-Response Relationship, Drug; Endothelial Cells; Erythromycin; Flow Cytometry; Humans; Levofloxacin; Ofloxacin; Phlebitis; Virginiamycin | 2006 |
In-vitro activity of quinupristin/dalfopristin, levofloxacin and moxifloxacin against fusidic acid and rifampicin-resistant strains of methicillin-resistant Staphylococcus aureus (MRSA) from Malaysian hospitals.
Topics: Anti-Bacterial Agents; Aza Compounds; Disease Susceptibility; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Fusidic Acid; Humans; In Vitro Techniques; Levofloxacin; Malaysia; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Rifampin; Staphylococcus aureus; Virginiamycin | 2005 |
[Comparative study of treatment with quinupristin-dalfopristin alone or in combination with gentamicin, teicoplanin, imipenem or levofloxacin in experimental endocarditis due to a multidrug-resistant Enterococcus faecium].
Topics: Aged; Animals; Anti-Bacterial Agents; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Endocarditis, Bacterial; Enterococcus faecium; Female; Gentamicins; Gram-Positive Bacterial Infections; Humans; Imipenem; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Rabbits; Teicoplanin; Virginiamycin | 2006 |
Effect of quinupristin/dalfopristin on 3T3 and Eahy926 cells in vitro in comparison to other antimicrobial agents with the potential to induce infusion phlebitis.
Topics: Animals; Anti-Bacterial Agents; BALB 3T3 Cells; Cell Survival; Dose-Response Relationship, Drug; Endothelial Cells; Erythromycin; Fibroblasts; Humans; Infusions, Intravenous; Inhibitory Concentration 50; Levofloxacin; Mice; No-Observed-Adverse-Effect Level; Ofloxacin; Phlebitis; Reproducibility of Results; Toxicity Tests; Virginiamycin | 2007 |